Recent Updates — SVA

Sinovac Biotech Ltd. reported unaudited financial results for the first half of 2026 ending June 30, 2026. Total sales increased 12.9% to $147.1 million from $130.3 million in the prior year period, driven by an 82.3% surge in overseas revenue to $66.5 million. The company posted a net loss attributable to common shareholders of $60.2 million, or $0.84 per share, compared to a $21.7 million loss, or $0.30 per share, in the prior year period. Gross profit margin expanded to 65.0% from 62.5%, while selling, general and administrative expenses decreased to $130.9 million due to efficiency improvements. Subsequent to the reporting period, Sinovac received NMPA marketing approval for its rabies vaccine (PVRV-SF) on August 4, 2026, and the NDA for its bivalent enterovirus vaccine was accepted for priority review. The company holds $998.5 million in cash and equivalents as of June 30, 2026. Sinovac Biotech Ltd. is a global biopharmaceutical company headquartered in China dedicated to the research, development, manufacturing, and supply of vaccines.